2023 ESMO Highlights Webinar-2023 ESMO Highlights

Video Transcription
Video Summary
The ELCC webinar focused on 2023 ESMO highlights discussed several studies that were presented at the ESMO meeting. Dr. Elena Linardou talked about studies on new agents with novel mechanisms of action, such as antibody-drug conjugates (ADCs) and bispecific antibody combinations for non-small cell lung cancer. She highlighted the Tropium Lung-01 study, which investigated an ADC called DATO-Texasamab in the second line treatment of non-small cell lung cancer. The study showed that DATO-Texasamab had a statistically significant benefit in progression-free survival compared to standard of care treatment with docetaxel. However, the benefit seemed to be more pronounced in patients with non-squamous histology. Dr. Linardou also discussed the Mariposa studies, which investigated an ADC combination with a targeted agent and chemotherapy for FGFR-mutated non-small cell lung cancer. Lastly, she talked about the Delphi-301 study, which investigated a novel bispecific T-cell engager for extensive stage small cell lung cancer. Dr. Thelma Sequeira then presented on new targeted agents and their potential as new standards of care. She discussed the ELIANA study, which investigated the use of adjuvant electinib for ALK-positive early stage non-small cell lung cancer. The study showed that adjuvant electinib had a statistically significant improvement in disease-free survival compared to standard of care treatment with chemotherapy. She also discussed the LIBRETO-431 study, which investigated the use of Selpercatinib as a first-line treatment for RET-positive non-small cell lung cancer. The study showed that Selpercatinib had a statistically significant improvement in progression-free survival compared to standard of care treatment with chemotherapy. Lastly, Dr. Tomeu Massuti presented on perioperative treatment with chemo-immunotherapy in early-stage non-small cell lung cancer. He discussed the KEYNOTE-C7-1 trial, which investigated the use of perioperative pembrolizumab with chemotherapy followed by postoperative pembrolizumab for non-small cell lung cancer. The trial showed that perioperative pembrolizumab had a statistically significant improvement in overall survival compared to placebo. He also discussed the CHECKMATE-77T trial, which investigated the use of neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab for non-small cell lung cancer. The trial showed a positive result in terms of event-free survival, with a statistically significant improvement in event-free survival compared to placebo. Overall, the webinar provided insights into the latest studies and developments in the treatment of lung cancer.
Keywords
ELCC webinar
2023 ESMO highlights
non-small cell lung cancer
ADCs
bispecific antibody combinations
Tropium Lung-01 study
DATO-Texasamab
progression-free survival
adjuvant electinib
perioperative treatment